Skip to content

Study · In vitro (cells) · 2009

2 results

Growth hormone excess promotes breast cancer chemoresistance.

Zatelli MC, Minoia M, Molè D, Cason V, Tagliati F, Margutti A, Bondanelli M, Ambrosio MR, degli Uberti E

The Journal of clinical endocrinology and metabolism21 Jul 2009Cited by 38 (Europe PMC)

PMID19622619 (opens in a new tab)DOI10.1210/jc.2009-1026 (opens in a new tab)PepBankPUB-19622619
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In MCF7 breast cancer cells, pegvisomant inhibited basal c-fos promoter transcriptional activity.

    In plain wordsIn cells, pegvisomant inhibited basal c-fos promoter activity.

    Peptide
    Pegvisomant
    Outcome
    DecreaseBasal c-fos promoter transcription
    Study

    humann: not reported in source

    MCF7 breast cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pegvisomant inhibited basal and GH-induced c-fos promoter transcriptional activity.
    1 context sentence
    Summary · context
    We evaluated GH and IGF-I effects on cell proliferation of a BC cell line, MCF7 cells, in the presence of doxorubicin (Doxo), frequently used in BC chemotherapy, and the possible mechanisms involved.
  2. 02LabIn vitro (cells)Mechanism

    In MCF7 breast cancer cells, pegvisomant inhibited GH-induced c-fos promoter transcriptional activity.

    In plain wordsIn cells, pegvisomant reduced c-fos promoter activity compared with growth hormone stimulation alone.

    Peptide
    Pegvisomant
    Outcome
    DecreaseGH-induced c-fos promoter transcription
    Study

    humann: not reported in source

    MCF7 breast cancer cells
    Comparator
    GH stimulation without pegvisomant
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pegvisomant inhibited basal and GH-induced c-fos promoter transcriptional activity.
    1 context sentence
    Summary · context
    We evaluated GH and IGF-I effects on cell proliferation of a BC cell line, MCF7 cells, in the presence of doxorubicin (Doxo), frequently used in BC chemotherapy, and the possible mechanisms involved.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.